Lido Advisors’s Inozyme Pharma INZY Stock Holding History

Lido Advisors’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,108	Closed	-$131K	–	1446
2024 Q1	$131K	Buy	+17,108	New	+$93.9K	﹤0.01%	1309

Other funds holding INZY

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lido Advisors's INZY Position: Q2 2024 in Review

Lido Advisors sold out of Inozyme Pharma (INZY) in Q2 2024, closing a stake of 17,108 shares — an estimated $131K sold.

Lido Advisors first reported a position in INZY in Q1 2024 and held it in 1 quarter. The position peaked at $131K in Q1 2024. 90 funds tracked by Wall St. Rank hold INZY as of Q2 2024.

Lido Advisors reported no remaining Inozyme Pharma position as of Q2 2024 after selling out during the quarter.
Lido Advisors sold 17,108 Inozyme Pharma shares in Q2 2024, an estimated $131K.
Lido Advisors first reported a position in Inozyme Pharma in Q1 2024 and held it in 1 quarter.
Lido Advisors's Inozyme Pharma position peaked at $131K in Q1 2024.
90 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2024.

Based on Lido Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.